Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-599-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110215.30.2-599-000"2
lpv:hasSubsequent	lp_eu:2011-02-15-Speech-2-600-0002
lpv:speaker	lp:Gilles Pargneaux2
lpv:spokenAs	member; Delegation for relations with Canada (2009-09-16--2014-06-30)3 unknown; Parti socialiste (2009-07-14--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation for relations with the United States (2009-09-16--2012-07-03)3 member; S&D (2009-07-14--2014-06-30)3 substitute; TRAN (2009-07-16--2012-01-18)3
lpv:translated text	"Madam President, I would like to raise one more point in the light of the comments made and the responses given by Commissioner Dalli, whom I would like to thank for the clarifications provided. As you pointed out, Commissioner, in 2003 and 2005, it was Servier which asked for the product to be withdrawn from sale in these two countries. You also said that in 1998 and 1999, the working party chose neither to authorise nor propose the withdrawal of this product. Yet we know that the medicinal product was withdrawn in the United States in 1997. Therefore, surely it is clear – and here is the nub of the matter – that in a market as large as the European Union, which encompasses 500 million European citizens, we need more vigilance? In particular, we need additional alerts that will trigger Europe-wide action, with clear competences for the European Commission and the European Medicines Agency. In this way, we will be able to avoid a repeat of the situations that have occurred in some Member States, such as the French case that was cited."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph